A3P Biomedical supports the Public Health Agency of Sweden in responding to challenges posed by covid-19

April 14, 2020

A3P Biomedical announced today that while continuing the fight against prostate cancer, providing the unique blood-based prostate cancer test Stockholm3, the company is committed to supporting government efforts in responding to covid-19.

A3P Biomedical announced today the company will provide resources to support government efforts in responding to covid-19. At the same time, A3P continues to provide the unique blood-based prostate cancer test Stockholm3. As an official partner to the Public Health Agency of Sweden, A3P utilizes part of its laboratory capabilities and infrastructure to support covid-19 PCR testing efforts.

“Our covid-19 analysis will follow the guidelines of the Public Health Agency of Sweden. We are happy to be able to support the government in this effort. We have the technical competence, suitable equipment and an entrepreneurial spirit to quickly refocus part of our lab resources for analyzing covid-19 tests. We will of course continue our testing for prostate cancer with Stockholm3” Martin Steinberg CEO of A3P Biomedical.

A23 lab AB is a fully owned subsidiary of A3P Biomedical. An interview with the founders, in the daily newspaper DN, can be found here.